Yes I agree on the long term CSL will do well with $1B R&D budget. But on the short term with this uncertainty on their revenue, I doubt investors will be paying high PE multiple. CSL will have to demonstrate some visible potential products which are almost ready for the market or Vifor & Vaccine business come up with compensating increase in revenue. I think that is there issue at the moment.
UBS - CSL no need to worry about Argenx, page-7
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$308.88 |
Change
1.020(0.33%) |
Mkt cap ! $149.5B | |||
| Open | High | Low | Value | Volume |
| $307.95 | $310.00 | $306.26 | $88.06M | 285.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25 | $308.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $308.89 | 177 | 14 |
View Market Depth
| Last trade - 14.12pm 17/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |